SVB Leerink Upgrades Pacira Pharmaceuticals (PCRX) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Price: $36.35 +0.11%
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Join SI Premium – FREE
SVB Leerink analyst Ami Fadia upgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Market Perform to Outperform with a price target of $44.00 (from $46.00).
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $32.52 yesterday.
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $220 at BMO Capital
- Northland Upgrades c3.ai (AI) to Outperform
- Largan Precision Co Ltd. (3008:TT) PT Raised to NT$4,752 at Macquarie
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
